The Battle Between Tumors and Complement
The complement system, as an important component of the body’s immune system, plays a key role in tumor development and therapy. Tumor immunomodulation by the complement system has a dual role inRead More…
The complement system, as an important component of the body’s immune system, plays a key role in tumor development and therapy. Tumor immunomodulation by the complement system has a dual role inRead More…
CD35, also known as complement receptor 1 (CR1), plays a crucial role in the complement system. The complement system is part of the immune system that recognizes and removes pathogens, promotes inflammatoryRead More…
Structure of Complement Regulatory Protein Factor H Complement Factor H, also known as Factor H and CFH, is a sialic acid-containing glycoprotein that plays an integral role in regulating the complement-mediated immuneRead More…
Dianthus Therapeutics’ (DNTH) primary asset is DNTH103, a selective monoclonal antibody targeting the active form of complement C1s. The main focus is a me-better version of Sanofi’s already-marketed C1s monoclonal antibody, Sutimlimab.Read More…
The complement system plays a crucial role in the body’s defense against harmful invaders. It is an essential component of the innate immune response, and its end products, C3a and C5a, exertRead More…
Complement is an essential component of the intrinsic immune system, comprising a set of serum-functioning proteasome cascade pathways that play a crucial role in clearing invading pathogens and senescent dying cells. ProteaseRead More…
The complement system is an important part of the innate and adaptive immune system. When activated, it participates in the body’s defense response and immune regulation, including enhancing antibody response, possessing immuneRead More…
The increasing number of clinical diseases involving pathological contributions of the complement system has prompted renewed interest in therapeutic options to modulate this host defense pathway. Based on these findings, the pharmaceuticalRead More…
The complement system, a vital component of innate immunity and a potent promoter of inflammation, has a crucial role in host defense against pathogens and the development of central and peripheral nervousRead More…
On February 17, 2023, Apellis announced the FDA approval of Pegcetacoplan, a complement C3 inhibitor, as the first molecularly targeted drug for the treatment of dry AMD or geographic atrophy. This approvalRead More…